English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNew findings from a global team of expert scientists in academia and industry has generated world-first research quality standards that will help slash costs and reduce the time it takes to develop advanced nanomedicine treatments and make them available for patients.
Tag: mRNA and COVID-19
Long-Term Data Reveals SARS-CoV-2 Infection and Vaccine-Induced Antibody Responses Are Long-Lasting
New study results challenge the idea that vaccine immunity fades quickly
Children’s Hospital Los Angeles Study of Childhood COVID-19 Immunity Could Safeguard Babies Too Young for COVID-19 Vaccination
Pia Pannaraj, MD, MPH, an infectious disease specialist at Children’s Hospital Los Angeles, was awarded $4.2 million from the National Institutes of Health to study COVID-19 immunity in children.
Cancer Patients Treated with Immunotherapy Can Safely Receive mRNA COVID-19 Vaccines, According to JNCCN Study
New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment.
Incidence of Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States
In this population-based surveillance, the authors found that myocarditis/pericarditis 0 to 7 days after mRNA vaccination in persons aged 5 to 39 years occurred in approximately 1 in 200,000 doses after the first dose and 1 in 30,000 doses after second dose of the primary series, and 1 in 50,000 doses after the first booster. The incidence varied markedly by age and sex, however, with a disproportionate number of cases occurring in male persons, notably among adolescents after dose 2 and first boosters.